Mirabegron: pharmacoeconomic aspects of the use of the drug for the treatment of overactive bladder syndrome

According to the International Continence Society (ICS), symptoms of overactive bladder (OAB) are present in 17 % of the adult population of Europe. The prevalence of overactive bladder in Russia is unknown but is considered comparable to that in European countries. According to Russian guidelines, patients with OAB could be treated with antimuscarinics or beta 3-agonists. The results of a meta-analysis by Wang J et al. (2018) showed comparable efficacy and safety of mirabegron and solifenacin. At the same time, according to Chapple CR et al. (2017) and Yeowell G et al. (2018) the use of mirabegron is associated with greater adherence to therapy and longer average drug use before the need to change therapy compared to antimuscarinics. From an economic point of view, greater adherence to drug therapy is associated with lower costs per patient with OAB per year and mirabegron have demonstrated to be cost-eff ective in comparison to solifenacin. The results of the analysis of the structure and volume of providing various types of medical care to patients with OAB in the Moscow region demonstrate the need to expand approaches to providing drug care to this group of patients. Currently, the majority of costs related to patients with OAB are associated with surgical treatment, which indicates the opportunity to expand the possibilities of drug therapy, including within the framework of preferential drug provision.

1. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002 Nov;60(5 Suppl 1):7–12; discussion 12. doi:10.1016/s0090-4295(02)01784-3

2. ICS Fact Sheets 2015. URL: https://www.ics.org/folder/news-and-publications/ics-factsheets/d/ics-fact-sheets-2015.

3. Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K, EPIC Study Group. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int. 2008;101(11):1381–7. doi:10.1111/j.1464-410x.2008.07573.x

4. Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin. 2007;23(1):65–76. doi:10.1185/030079907X159533

5. Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, Tubaro A. EAU Guidelines on Urinary Incontinence. Arnhem: EAU Guidelines Office, 2020. URL: https://uroweb.org/guideline/urinary-incontinence/.

6. Krivoborodov GG, Tur EI, Shirin DA. Hyperactive bladder: concept of disease and paradigms in the treatment. Meditsinskiy sovet = Medical Council. 2021;(4):121–6. (In Russ). doi:10.24411/2588-0519-2018-10034

7. Kolbin AS, Vilyum IA, Proskurin MA, Balykina YuE. Farmakoehkonomicheskaya ocenka primeneniya mirabegrona: rezultaty analiza vliyaniya na byudzhet zdravoohraneniya. Kachestvennaya klinicheskaya praktika [Pharmacoeconomic evaluation of mirabegron: results of the healthcare budget impact analysis. Good Clinical Practice]. 2018;(1):15–24. (In Russ). doi:10.24411/2588-0519-2018-10034

8. Дьяков И. Н., Касян Г. Р. Фармакоэкономическая целесообразность применения препарата мирабегрон у больных с гиперактивным мочевым пузырём. Качественная клиническая практика. 2021;(1):35–45. (In Russ). doi:10.37489/2588-0519-2021-1-35-45

9. Нейрогенная дисфункция нижних мочевыводящих путей: клинические рекомендации. URL: https://cr.minzdrav.gov.ru/schema/588_2. Ссылка активна на 05.03.2022.

10. Kasyan GR, Khodyreva LA, Dudareva AA, Tupikina NV, Pushkar DYu. Sindrom giperaktivnogo mochevogo puzyrya v klinicheskoj praktike vrachaurologa: metodicheskie rekomendacii № 13. Moscow, 2019. (In Russ).

11. Wang J, Zhou Z, Cui Y, Li Y, Yuan H, Gao Z, Zhu Z, Wu J. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn. 2019;38(1):22–30. doi:10.1002/nau.23863

12. Chapple ChR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Eur Urol. 2017;72(3):389–99. doi:10.1016/j.eururo.2017.01.037

13. Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018 Nov 21;8(11):e021889. doi:10.1136/bmjopen-2018-021889

14. Scaglione F. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice. Toxins (Basel). 2016 Mar 4;8(3):65. doi:10.3390/toxins8030065

15. Kliniko-ekonomicheskij analiz / ed. by PA Vorobyov. Moscow: Newdiamed, 2019. (In Russ).

16. Overactive Bladder – Epidemiology Forecast to 2030. Global Data. URL: https://www.reportlinker.com/p06179759/Overactive-Bladder-EpidemiologyForecast-to.html?utm_source=GNW.